TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06777979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD19-CD22 CAR T cell infusion
Description: CAR T cell infusion will be given intravenously, either centrally or peripherally.
Study: NCT06777953

Intervention type: OTHER
Intervention: Erector Spinae (ESP) Block with Lidocaine/Bupivacaine
Description: This study is to retrospectively compare the analgesic efficacy and impact on postoperative recovery of popliteal sciatic nerve blocks and Lumbar-Sacral Erector Spinae Plane blocks administered for postoperative pain management in tibial fractures.

Intervention type: OTHER
Intervention: Popliteal Sciatic Nerve Block
Description: This study is to retrospectively compare the analgesic efficacy and impact on postoperative recovery of popliteal sciatic nerve blocks and Lumbar-Sacral Erector Spinae Plane blocks administered for postoperative pain management in tibial fractures.
Study: NCT06778954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (Peritoneal application group)
Description: At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is applied on space between peritoneum and fascia in Arm I.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arm I (Peritoneal application group)
Description: At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is applied on space between peritoneum and fascia in Arm I.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arm II (Subcutaneous injection group)
Description: At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is injected on subcutaneous area in Arm II.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm II (Subcutaneous injection group)
Description: At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is injected on subcutaneous area in Arm II.
Study: NCT06778720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy with over-the ear headphones
Description: Eligible patients undergoing VATS procedure can have music therapy as an intervention to reduce pain levels after surgery and improve outcomes.
Study: NCT06778876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lavender sachet group
Description: The normal procedure applied in the sleep clinic (keeping a sleep diary, sleep hygiene education) will be followed and participants will be asked to sleep with lavender sachets inside their pillows for two weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control group
Description: Participants will follow the normal procedure applied (keeping a sleep diary, sleep hygiene training) in the sleep clinic and no additional intervention will be performed.
Study: NCT06778486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Chatbot
Description: The intervention is a generative artificial intelligence large language model chatbot that has a structured prompt with fill-in-the-blank style questions that the participant will complete.
Study: NCT06779617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEPSys
Description: The SEPSys Score is a clinical decision support tool for predicting the risk of developing sepsis in the next 4 hours. The SEPSys Score produces a 1-4, color-coded risk, where 4 (red) is the highest risk and 1 (green) is the lowest risk.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEPSys
Description: The SEPSys Score is a clinical decision support tool for predicting the risk of developing sepsis in the next 4 hours. The SEPSys Score produces a 1-4, color-coded risk, where 4 (red) is the highest risk and 1 (green) is the lowest risk.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESCUE
Description: The RESCUE Score is a clinical decision support tool for predicting the risk of patient experiencing clinical deterioration (cardiac arrest, rapid response team call, death, or unplanned increase in care) in the next 4 hours. The RESCUE Score produces a 1-4, color-coded risk, where 4 (red) is the highest risk and 1 (green) is the lowest risk.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESCUE
Description: The RESCUE Score is a clinical decision support tool for predicting the risk of patient experiencing clinical deterioration (cardiac arrest, rapid response team call, death, or unplanned increase in care) in the next 4 hours. The RESCUE Score produces a 1-4, color-coded risk, where 4 (red) is the highest risk and 1 (green) is the lowest risk.
Study: NCT06778395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexlansoprazole 60 mg
Description: once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan 20 mg bid
Description: twice daily for 8 weeks
Study: NCT06777758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam
Study: NCT05547399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered orally as a tablet or capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered orally as a tablet or capsule
Study: NCT05570760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptos®Ortho Wedge (bone grafting surgery)
Description: After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: OWHTO without bone grafting
Description: After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation, without bone grafting. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
Study: NCT06700083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 placebo
Description: SHR-6934 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6934 placebo
Description: SHR-6934 placebo
Study: NCT05570760

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chronOS® Wedge (bone grafting surgery)
Description: After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
Study: NCT06650748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib, oral administration, 125g each time, once daily, days 1-21, with a 28-day cycle (3 weeks on/1 week off). Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib, oral administration, 125g each time, once daily, days 1-21, with a 28-day cycle (3 weeks on/1 week off). Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage
Study: NCT06657391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant humanized anti-CD25 monoclonal antibody
Description: The intervention group received 4 doses of recombinant humanized anti-CD25 monoclonal antibody on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.
Study: NCT06658990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: buccal acupuncture
Description: ultrasound positioning assisted buccal acupuncture
Study: NCT05082909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Addition of 500mg QDS to oral penicillin.
Study: NCT05141695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: therapeutic repetitive peripheral magnetic stimulation
Description: Patients in the treatment group will receive peripheral magnetic stimulation therapy for the upper extremity arm/forearm spastic muscles on the hemiplegic side for a total of ten sessions once a day, five sessions a week, for two weeks, each session lasting ten minutes. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive peripheral magnetic stimulation
Description: rPMS will not be given to the sham group, the device will not be operated, the probe of the device will be positioned in the same way as the patients in the treatment group for ten minutes, and the sounds recorded during the operation of the device will be heard by the patients. Patients and evaluators will not know which group the patients are in. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
Study: NCT06513962

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT06698952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The intervention group will engage with SPI-Bot, a conversational agent designed to deliver cognitive and behavioral strategies for managing psychological symptoms through fully automated interactions. SPI-Bot operates on a template-based platform with predefined dialogue options, utilizing natural language processing technology. The intervention spans eight weeks and includes key components such as psychoeducation, cognitive restructuring, relaxation training, activity scheduling, problem-solving skills training, and social skills training. Participants will complete one session per week over the eight-week period. Participants will receive weekly contact from the research team to report AIS symptoms, receive homework reminders, and address any intervention-related questions.
Study: NCT06658990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Sufentanil is used after surgery
Study: NCT06660979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement learning
Description: The intervention is a reinforcement learning program that personalizes EHR-based tools for PCPs to promote deprescribing high-risk medications over follow-up. The reinforcement learning intervention selects a tool for each provider based on an algorithm from an inventory of EHR tools and chooses tools that are predicted to motivate action for the individual provider. The inventory of EHR tools from which the algorithm will choose include the following potential factors: open encounter, order entry, cold-state outreach, simplification, and risk framing.
Study: NCT06658210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soft tissue mobilization with pelvic floor muscle exercises
Description: Group A will receive soft tissue mobilization and pelvic floor muscle exercises. Soft tissue mobilization technique will include abdominal myofascial release/trigger point release and deep scar mobilization to decrease pain and improve scar mobility

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soft tissue mobilization without pelvic floor muscle exercises
Description: Group B will receive soft tissue mobilization technique without pelvic floor exercises.
Study: NCT06658444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phonophoresis
Description: Pulsed ultrasound will be used at a frequency of 1 MHz with an intensity of 0.5 W/ cm2 for 5 minutes.
Study: NCT06698952

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Participants in the control group will interact with a different generative chatbot, engaging in casual conversations at a similar dosage to ensure balanced attention and interaction effects.
Study: NCT06699758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors.
Description: CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors. These cells will be administered intranasally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors.
Description: CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors. These cells will be administered intranasally.
Study: NCT06513962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate
Description: Given IM
Study: NCT05758077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Cytopheretic Device
Description: The Selective Cytopheretic Device (SCD) is comprised of tubing, connectors, and a synthetic hollow fiber membrane cartridge. The device is connected in series to a commercially available CKRT hemofilter. Blood from the CKRT circuit is diverted after the CKRT hemofilter through to the extracapillary space (ECS) of the SCD cartridge. Blood circulates through the SCD ECS and then it is returned to the patient via the venous return line of the CKRT circuit. Regional citrate anticoagulation is used for the entire CKRT and SCD blood circuit.~The SCD cartridge incorporates a synthetic hollow fiber membrane with the ability to bind activated leukocytes to its extracapillary surface; and when used in a CKRT extracorporeal circuit in the presence of regional citrate anticoagulation, the SCD modulates inflammation.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care CKRT for the subject's condition, as appropriate
Study: NCT06061913

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breast Pump suction pattern
Description: Mothers who have reached secretory activation and are pumping \<350 mLs/day will be randomized to one of three breast pump suction patterns.
Study: NCT06658444

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham ultrasound
Description: sham ultrasound
Study: NCT06661174

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Laparoscopic sleeve gastrectomy or laparoscopic gastric bypass based on β-cell function

Intervention type: OTHER
Intervention: Non-surgical therapy
Description: Diet management，exercise，metformin，GLP-1 receptor agonists and other drugs which can lose weight.

Intervention type: OTHER
Intervention: Non-surgical therapy
Description: Diet management，exercise，metformin，GLP-1 receptor agonists and other drugs which can lose weight.
Study: NCT06061913

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breast Pump suction pattern
Description: Mothers who have reached secretory activation and are pumping \<350 mLs/day will be randomized to one of three breast pump suction patterns.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Breast Pump suction pattern
Description: Mothers who have reached secretory activation and are pumping \<350 mLs/day will be randomized to one of three breast pump suction patterns.
Study: NCT06699758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors.
Description: CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors. These cells will be administered intranasally.
Study: NCT06353334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide and Sodium Chloride Injection
Description: All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP twice daily. Each patient will receive continuous medication for 14 days.
Study: NCT04421079

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Trans-resveratrol
Description: 150mg, 300mg, 450mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Trans-resveratrol
Description: 150mg, 300mg, 450mg
Study: NCT06658717

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Investigational product (IP): Natural orange extract
Description: Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
Study: NCT06353334

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
Study: NCT06658717

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Group II: Placebo: Microcrystalline cellulose (MCC)
Description: Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
Study: NCT05611346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: The experimental group will receive 2 standardized hypnosis sessions via the superhero costume technique performed during this collective therapeutic education program, completed by a reinforcement through the practice of self-hypnosis at home guided by the listening of an audio recording
Study: NCT04421079

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Trans-resveratrol
Description: 150mg, 300mg, 450mg
Study: NCT06658652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide decanoate
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide decanoate
Description: Oral tablet
Study: NCT04421079

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Concord grape juice
Description: 8 oz, 16 oz, 24 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Concord grape juice
Description: 8 oz, 16 oz, 24 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Concord grape juice
Description: 8 oz, 16 oz, 24 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed polyphenol extract
Description: 450mg, 900mg, 1200mg

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed polyphenol extract
Description: 450mg, 900mg, 1200mg
Study: NCT05396638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants will be paid for abstinence at each study visit.
Study: NCT04421079

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed polyphenol extract
Description: 450mg, 900mg, 1200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparable placebo supplement which is manufactured according to GMP and will contain inert substances.
Study: NCT05325866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Intravenous (IV) infusion.
Study: NCT05331170

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Research Grade RG-RV
Description: Exploration of the effects of RV inoculation on human airway mucosal programming in vivo

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Research Grade RG-RV
Description: Exploration of the effects of RV inoculation on human airway mucosal programming in vivo